1. Home
  2. BDSX vs LCTX Comparison

BDSX vs LCTX Comparison

Compare BDSX & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • LCTX
  • Stock Information
  • Founded
  • BDSX 2005
  • LCTX 1990
  • Country
  • BDSX United States
  • LCTX United States
  • Employees
  • BDSX N/A
  • LCTX N/A
  • Industry
  • BDSX Precision Instruments
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • BDSX Health Care
  • LCTX Health Care
  • Exchange
  • BDSX Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • BDSX 115.4M
  • LCTX 107.3M
  • IPO Year
  • BDSX 2020
  • LCTX N/A
  • Fundamental
  • Price
  • BDSX $0.26
  • LCTX $0.90
  • Analyst Decision
  • BDSX Strong Buy
  • LCTX Strong Buy
  • Analyst Count
  • BDSX 5
  • LCTX 5
  • Target Price
  • BDSX $1.75
  • LCTX $4.20
  • AVG Volume (30 Days)
  • BDSX 2.9M
  • LCTX 2.4M
  • Earning Date
  • BDSX 08-06-2025
  • LCTX 08-07-2025
  • Dividend Yield
  • BDSX N/A
  • LCTX N/A
  • EPS Growth
  • BDSX N/A
  • LCTX N/A
  • EPS
  • BDSX N/A
  • LCTX N/A
  • Revenue
  • BDSX $74,463,000.00
  • LCTX $9,557,000.00
  • Revenue This Year
  • BDSX $17.29
  • LCTX N/A
  • Revenue Next Year
  • BDSX $29.33
  • LCTX $232.66
  • P/E Ratio
  • BDSX N/A
  • LCTX N/A
  • Revenue Growth
  • BDSX 35.76
  • LCTX 19.42
  • 52 Week Low
  • BDSX $0.17
  • LCTX $0.37
  • 52 Week High
  • BDSX $2.04
  • LCTX $1.15
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 38.93
  • LCTX 74.23
  • Support Level
  • BDSX $0.27
  • LCTX $0.67
  • Resistance Level
  • BDSX $0.33
  • LCTX $0.83
  • Average True Range (ATR)
  • BDSX 0.03
  • LCTX 0.06
  • MACD
  • BDSX 0.01
  • LCTX 0.02
  • Stochastic Oscillator
  • BDSX 19.54
  • LCTX 84.94

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: